Boule Diagnostics First Quarter 2025 Earnings: Misses Expectations

Boule Diagnostics (STO:BOUL) First Quarter 2025 Results

Key Financial Results

• Revenue: kr112.9m (down 24% from 1Q 2024).
• Net loss: kr10.3m (down by 205% from kr9.80m profit in 1Q 2024).
• kr0.27 loss per share (down from kr0.25 profit in 1Q 2024).

We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Boule Diagnostics Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 20%. Earnings per share (EPS) also missed analyst estimates by 6.6%.

Looking ahead, revenue is forecast to grow 4.4% p.a. on average during the next 3 years, compared to a 14% growth forecast for the Medical Equipment industry in Sweden.

Performance of the Swedish Medical Equipment industry.

The company's shares are down 3.1% from a week ago.

Risk Analysis

You should learn about the 1 warning sign we've spotted with Boule Diagnostics.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.